Valuation of some markers in the malignant neoplastic pathology of the female genital tract.
The Authors studied the presence of some markers in different gynaecological tumours, by radioimmunoassay. Beta-HCG, 1-alfa-FP, CA 125, GICA and TPA were assayed in 76 patients. Eight of the patients were affected by CIN III, 38 presented a cervical carcinoma (10 at stage I, 14 at stage II, 10 at stage III, 4 at stage IV); 14 patients had an endometrial adenocarcinoma (3 at stage I, 7 at stage II, 2 at stage III and II at stage IV); 12 cases consisted of an ovarian carcinoma with 2 patients at stage I, 5 at stage II and 5 at stage III; 2 patients had a peritoneal diffusion, whereas two women presented a vulvar carcinoma; the control group was formed by 10 patients with no malignant or benign pathology. The results show that tumoral markers, studied in the blood of patients affected by malignant gynaecological tumours, represent a great advantage in the evaluation of both the response to the therapy and of an eventual remission or tumoral recurrence.
Restaino
A
A
I Gynaecological Institute, University of Bari, Italy.
Traina
V
V
Putignano
G
G
Fanizza
G
G
Miniello
G
G
Vicino
M
M
Malvasi
A
A
D014408:Biomarkers, Tumor / Q000097:blood*; D005260:Female; D005833:Genital Neoplasms, Female / Q000097:blood / Q000473:pathology*; D006801:Humans; D009367:Neoplasm Staging; D011379:Prognosis; D011863:Radioimmunoassay
D014408:Biomarkers, Tumor